Iptacopan reached French PNH patients via AP1 two weeks before its EU marketing authorisation.
France's Accès Précoce (AP) framework, reformed under the 2021 Social Security Financing Law and Décret n°2021-869 (30 June 2021), runs two tracks: AP1 covers innovative medicines before marketing authorisation (AMM), while AP2 covers medicines that already hold an AMM but are not yet reimbursed under Assurance Maladie. Eligibility rests on four cumulative criteria set by the Haute Autorité de Santé (HAS): serious, rare or disabling disease; no appropriate alternative treatment; treatment cannot be deferred; and presumed innovative status versus the relevant comparator. Iptacopan (Fabhalta) used this route directly: HAS's Collège granted accès précoce authorisation n°2024.0128/DC/SEM on 2 May 2024, two weeks before Fabhalta's EU-wide marketing authorisation took effect on 17 May 2024, confirming an AP1, pre-AMM entry for PNH in France.
For a new PNH entrant, this means the accès précoce dossier, not the post-AMM Commission de la Transparence submission, is the first gate. HAS's median processing time across all early-access requests was 80 days in 2023, against a regulatory ceiling of three months. Manufacturers must be ready to declare an indicative ex-tax price to CEPS at authorisation, since annual rebates accrue on invoiced turnover from day one, and a retrospective rebate reconciles the early-access price against the definitive CEPS-negotiated price once the standard SMR/ASMR appraisal closes. Iptacopan's own definitive appraisal did not land until seven months later, when HAS's Commission de la Transparence rated it ASMR III on 5 December 2024, restricted to second-line PNH.
Two access tracks, one outcome: AP1 and AP2 both feed into the same CEPS price reconciliation.
| Dimension | AP1 (Pre-AMM) | AP2 (Post-AMM) |
|---|---|---|
| Trigger point | Before EU marketing authorisation | After EU marketing authorisation, before a reimbursement price is fixed |
| Governing decision | HAS Collège decision, per the 2021 reform | Same HAS Collège decision process, same four cumulative criteria |
| Price/rebate mechanism | Indicative price declared; rebates accrue on invoiced turnover from day one | Same rebate mechanism; retrospective reconciliation to the definitive CEPS price |
| Iptacopan (Fabhalta) precedent | Confirmed: authorisation n°2024.0128/DC/SEM granted 2 May 2024, 15 days before 17 May 2024 EU marketing authorisation | Not confirmed in public HAS records; early access continued via AP1 renewal rather than a documented separate AP2 entry |
Sources: Haute Autorité de Santé, Décision n°2024.0128/DC/SEM du 2 mai 2024 (Fabhalta); European Commission, Brussels, 17.5.2024, C(2024) 3465 final; HAS, Rapport d'activité 2023 de la Commission de la Transparence; Ministère de la Santé, fiche procédures, remises et majoration pour l'accès précoce et l'accès compassionnel; Légifrance, Décret n°2021-869 du 30 juin 2021.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Precedent mapping of confirmed AP1/AP2 grants in PNH and adjacent complement-mediated indications, with decision numbers and dates verified against HAS's own record
Delivers
- A rebate/clawback exposure model benchmarked against iptacopan's and ravulizumab's published ex-tax prices and reimbursement scope
Delivers
- A dossier checklist and timeline mapped to HAS's three-month regulatory ceiling and iptacopan's actual seven-month gap to its definitive ASMR appraisal
Custom brief delivered in 72 hours.
Commission this briefWhat's inside
- The four cumulative HAS eligibility criteria
- How the 2021 reform (Décret n°2021-869) restructured early access
- The 2 May 2024 authorisation, 15 days ahead of EU marketing authorisation
- Timeline to the 5 December 2024 definitive ASMR III appraisal
- Indicative ex-tax price declaration at authorisation
- The retrospective rebate reconciliation to the CEPS-negotiated price
- HAS's 80-day median processing time vs the 3-month ceiling
- What a complete accès précoce dossier must contain
- Why every regulatory assumption, from accès précoce eligibility to the 80-day HAS processing window, carries an explicit confidence rating and source citation
- How pricing and rebate assumptions are benchmarked against iptacopan's and ravulizumab's own published ex-tax prices rather than estimated in isolation
- How iptacopan's actual timeline, AP1 authorisation 15 days before EU marketing approval then a seven-month wait to its definitive ASMR III appraisal, sets the sequencing benchmark
- Why pre-launch teams should prepare the accès précoce dossier against HAS's 80-day median processing time, not the 3-month regulatory ceiling
- Whether the client's PNH asset should pursue AP1 pre-AMM entry, following iptacopan's 2 May 2024 precedent, or wait for a post-AMM AP2 filing
- What ex-tax price to declare at accès précoce authorisation given the retrospective rebate exposure to CEPS's eventual negotiated price
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
This brief draws exclusively from primary regulatory sources: HAS's own decision record for Fabhalta's accès précoce authorisation, the European Commission's marketing-authorisation decision, and HAS's Commission de la Transparence activity report and doctrine documents governing the accès précoce evaluation process.
Primary sources cited: Haute Autorité de Santé, Décision n°2024.0128/DC/SEM du 2 mai 2024; European Commission, Brussels, 17.5.2024, C(2024) 3465 final; HAS, Rapport d'activité 2023 de la CT; Ministère de la Santé, fiche on remises and majoration for accès précoce/accès compassionnel; Légifrance, Décret n°2021-869 du 30 juin 2021.
- Iptacopan's accès précoce authorisation date (2 May 2024) and decision number were confirmed directly on the HAS website, not inferred from secondary summaries.
- The EU marketing authorisation date (17 May 2024) was cross-checked against the European Commission's own decision document, confirming the accès précoce grant preceded formal EU authorisation by two weeks.
- Whether iptacopan or any other PNH therapy has used the AP2 post-AMM track in France could not be confirmed in public HAS records; this brief states the AP1 precedent as confirmed and flags AP2 usage as unconfirmed rather than asserting it.
Frequently asked questions
Commission this assessment
AXLRx PNH Launch Readiness — France is built for commercial and market access teams preparing a French PNH launch, evaluating Accès Précoce pathway options, and building a dossier-readiness timeline. Custom brief in 72 hours.
Specify indication, geography, and launch timeline.
AXLRx analyst confirms pathway assumptions, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.